2011

In a recent video titled 'What Gets PhRMA's Chairman Up Every Morning?', Chris Viehbacher, CEO of Sanofi, cited an impressive Potemkin number related to life expectancy and the pharma industry.

In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'

The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude 'given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation's physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].' Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.

Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.

A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.

A Search Ad Format That Has All FDA Could Want... But Pharma Can't Use It! Data suggest that Google's OneBox NIH Rx ads effectively reduce organic search visitation driven to pharma sites pushing the traffic to NIH content instead. Is it logical to conclude that Google stands to gain paid ad revenue when pharma marketers have to compete with OneBox ads by buying more paid search placements to make up for the loss of organic search visits?

The whole web is now socialised..

Welcome to Volume 10, Issue #3 (17 FEBRUARY 2011) of Pharma Marketing News.